4DMedical Secures CE Mark for CT:VQ, Expands into Europe with A$83M Funding
Event summary
- 4DMedical's CT:VQ™ received CE Mark certification for commercial use in the European Union on March 30, 2026.
- The company secured A$83 million in private placement funding to support European expansion.
- CT:VQ™ is the world's first non-contrast, ventilation-perfusion imaging technology.
- The European market has an estimated 400,000 annual nuclear VQ scans, highlighting clinical need.
The big picture
4DMedical's CE Mark approval positions it to capitalize on Europe's advanced healthcare infrastructure and high demand for functional lung imaging. The A$83 million funding round underscores investor confidence in the company's ability to scale CT:VQ™, a technology that addresses long-standing limitations in nuclear VQ scanning. The strategic move into Europe follows successful U.S. deployments at major academic medical centers, signaling a broader push for global market penetration.
What we're watching
- Market Adoption
- How quickly CT:VQ™ will be integrated into European hospital workflows and whether it can replicate U.S. adoption success.
- Competitive Positioning
- Whether 4DMedical can sustain its lead in functional lung imaging against potential competitors.
- Regulatory Momentum
- The pace at which additional regulatory clearances could accelerate global commercialization.
Our editorial coverage: